Physician profile
William E Rietkerk
NPI 1720311400
$9,623.08
in general payments reported to CMS, 2019-2025
30 companies · $3,828 in 2025
The $3,828 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $503 · 2021: $192 · 2022: $929 · 2023: $1,760 · 2024: $1,919 · 2025: $3,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,173 · Consulting Fee: $1,950 · Education: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,173.25 |
| Consulting Fee | $1,950.00 |
| Education | $384.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,302.92 | 2021-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $1,025.51 | 2019-2025 | Dupixent |
| Genzyme Corporation | $925.05 | 2022-2025 | |
| Galderma Laboratories, L.P. | $912.32 | 2019-2025 | Aklief, Epsolay, Nemluvio |
| Sun Pharmaceutical Industries INC. | $870.61 | 2019-2025 | Winlevi, Ilumya, Odomzo |
| Abbvie INC. | $647.36 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $644.37 | 2021-2025 | Tremfya |
| Amgen INC. | $380.13 | 2022-2025 | Otezla, Otezla |
| Leo Pharma INC. | $372.82 | 2022-2025 | Adbry, Anzupgo |
| Pfizer INC. | $309.83 | 2022-2025 | |
| Lilly USA, LLC | $282.48 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Incyte Corporation | $150.65 | 2023-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $120.42 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $114.09 | 2020-2024 | Arazlo, Cabtreo, Jublia |
| Novartis Pharmaceuticals Corporation | $114.07 | 2022-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $100.01 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $67.01 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.90 | 2023-2024 | Spevigo |
| Merz North America, INC. | $28.69 | 2022 | |
| Organon LLC | $24.08 | 2025 | Vtama |
| Almirall LLC | $23.16 | 2020 | |
| Verrica Pharmaceuticals INC. | $22.97 | 2024 | Ycanth |
| Vyne Pharmaceuticals INC. | $22.47 | 2021 | |
| Organogenesis INC. | $22.45 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $20.75 | 2023 | |
| Biofrontera INC. | $18.42 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Cipher Pharmaceuticals US LLC | $16.00 | 2025 | Natroba, Spinosad |
| Lnhc, INC | $14.18 | 2025 | Zelsuvmi |
| Botanix Sb INC | $14.04 | 2025 | Sofdra |
| Epi Health, LLC | $12.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Rietkerk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.